After collecting billions of dollars in U.S. coronavirus aid, many of the nation’s wealthiest nonprofit hospitals are tapping into disaster relief funds that critics say they do not need.

Biogen Inc. agreed to pay $22 million to resolve U.S. allegations that the company illegally used two charities that help cover Medicare patients’ out-of-pocket drug costs as a means to pay them kickbacks to use the Cambridge, Mass-based drugmaker’s multiple sclerosis medicines.

Mallinckrodt filed for bankruptcy protection, saddled with lawsuits alleging the company helped fuel the U.S. opioid epidemic.

The COVID-19 pandemic has put a spotlight on the need for effective tools for quality measurement and reporting initiatives. Both Medicare and Medicaid are being impacted by changes to the way care is delivered and data is captured.

Gilead Sciences agreed to pay $97 million to resolve claims from the U.S. government that the company violated the False Claims Act.

President Donald Trump signed a new executive order aimed at lowering drug prices in the United States by linking them to those of other nations and expanding the scope of a July 2020 action.

Advanced Care Scripts Inc. will pay $3.5 million to resolve allegations that the Florida-based specialty pharmacy served as a conduit for a Teva Pharmaceutical Industries Ltd. subsidiary to pay kickbacks to Medicare patients, the U.S. Justice Department said.

One small pharma company is meeting the challenge of COVID-19 by finding new ways to support the practices of its specialist physician customers.

U.S. President Donald Trump signed four executive orders aiming at lowering prices that Americans pay for prescription drugs as he faces an uphill re-election battle and criticism over his handling of the coronavirus pandemic.

Novartis AG agreed to pay more than $729 million to settle U.S. government charges that the company paid illegal kickbacks to doctors and patients to boost drug sales, the U.S. Department of Justice said.